Semaglutide is a pure GLP-1 receptor agonist, meaning it targets only the GLP-1 pathway
Such an enhancer-driven approach now appears to be feasible for oral absorption of semaglutide, with phase 3 clinical trials ongoing
Last reviewed: May 14, 2026 Last updated: May 14, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
Generalizations such as one patient out of 10 had developed aspiration should not have been assumed as a 10% risk of aspiration for patients on GLP-1 RAs exists due to the sample size, for example
NuraPatch as a finished product has not been clinically studied
Ongoing testing is focused on evaluating the safety and composition of the seized products